Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases - PubMed (original) (raw)

Affiliations

PMID: 9558172

Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases

H Uesugi et al. J Rheumatol. 1998 Apr.

Abstract

Objective: To determine the immunodiagnostic value of antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, which have been identified as novel target antigens of perinuclear antineutrophil cytoplasmic antibodies (pANCA), in sera from patients with systemic rheumatic diseases.

Methods: Anti-HMG1 or HMG2 antibody was assayed by ELISA and Western blotting in sera from patients with systemic rheumatic diseases. These antibodies were analyzed for the relationship with pANCA detected by indirect immunofluorescence in these diseases, and with clinical features in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Results: Anti-HMG1 or HMG2 antibody was frequently detected in sera from patients with RA (48%), SLE (45%), Sjögren's syndrome (SS) (44%), and systemic sclerosis (SSc) (41%). In these diseases, anti-HMG1 antibody was detected more frequently than anti-HMG2 antibody. In sera from patients with RA, the positivity for anti-HMG1 and HMG2 antibodies was significantly correlated with the positivity for pANCA (p < 0.0001). Anti-HMG1/HMG2 antibodies were associated with some disease activity variables, e.g., erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, joint score and hand grip strength in RA, and CH50, C3, C4, and IgG in SLE.

Conclusion: Anti-HMG1/HMG2 antibodies are detected commonly in systemic rheumatic diseases, particularly in RA, SLE, SS, and SSc. HMGI and HMG2 seem to be the significant target antigens of pANCA in RA. These antibodies are significantly associated with disease activity indices in RA and SLE.

PubMed Disclaimer

Cited by

Emerging role of HMGB1 in fibrotic diseases.
Li LC, Gao J, Li J. Li LC, et al. J Cell Mol Med. 2014 Dec;18(12):2331-9. doi: 10.1111/jcmm.12419. Epub 2014 Oct 6. J Cell Mol Med. 2014. PMID: 25284457 Free PMC article. Review.
The spectrum of anti-chromatin/nucleosome autoantibodies: independent and interdependent biomarkers of disease.
Mehra S, Fritzler MJ. Mehra S, et al. J Immunol Res. 2014;2014:368274. doi: 10.1155/2014/368274. Epub 2014 Apr 3. J Immunol Res. 2014. PMID: 24804269 Free PMC article. Review.
Increased serum high mobility group box-1 level in Churg-Strauss syndrome.
Taira T, Matsuyama W, Mitsuyama H, Kawahara KI, Higashimoto I, Maruyama I, Osame M, Arimura K. Taira T, et al. Clin Exp Immunol. 2007 May;148(2):241-7. doi: 10.1111/j.1365-2249.2007.03347.x. Clin Exp Immunol. 2007. PMID: 17437420 Free PMC article. Retracted.
Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value.
van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. van Boekel MA, et al. Arthritis Res. 2002;4(2):87-93. doi: 10.1186/ar395. Epub 2001 Nov 6. Arthritis Res. 2002. PMID: 11879544 Free PMC article. Review.
Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?
Roozendaal C, Kallenberg CG. Roozendaal C, et al. Clin Exp Immunol. 1999 May;116(2):206-13. doi: 10.1046/j.1365-2249.1999.00905.x. Clin Exp Immunol. 1999. PMID: 10337008 Free PMC article. Review.

Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases - PubMed (original) (raw)